According to the official website of the State Drug Administration, AstraZeneca's “rilizumab” has been approved for a new domestic indication to treat paroxysmal nocturnal hemoglobinuria. Ralizumab was first approved for use in China in April 2025 to treat generalized myasthenia gravis in adults with positive anti-AChR antibodies, and was later extended to NMOSD. This is the 3rd indication that the drug has been approved domestically.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.